Antipsychotic drug-induced weight gain: development of an animal model (Q46408562)

21 December 2017

title

Antipsychotic drug-induced weight gain: development of an animal model (English)

1 reference

21 December 2017

1 reference

6

1 reference

21 December 2017

author name string

M B Cope

1

1 reference

21 December 2017

T R Nagy

2

1 reference

21 December 2017

J R Fernández

3

1 reference

21 December 2017

N Geary

4

1 reference

21 December 2017

D E Casey

5

1 reference

21 December 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

21 December 2017

International Journal of Obesity

published in

1 reference

21 December 2017

volume

29

1 reference

21 December 2017

issue

6

1 reference

21 December 2017

page(s)

607-614

1 reference

21 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.ijo.0802928

exact match

0 references

cites work

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Body weight gain induced by antipsychotic drugs: mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Studies on modulation of feeding behavior by atypical antipsychotics in female mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Systemic sulpiride increases dopamine metabolites in the lateral hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Characterization of olanzapine-induced weight gain in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Open-label quetiapine in the treatment of children and adolescents with autistic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Association of olanzapine-induced weight gain with an increase in body fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

A review of the effect of atypical antipsychotics on weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

Mechanism of the neuroleptic-induced obesity in female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

7 January 2021

Quantitation of olanzapine in tablets by HPLC, CZE, derivative spectrometry and linear voltammetry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

7 January 2021

Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

7 January 2021

Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0802928

7 January 2021

Identifiers

DOI

10.1038/SJ.IJO.0802928

1 reference

21 December 2017

PubMed ID

15795750

1 reference

21 December 2017